Top Page
Artrya Limited
(Sydney:AYA)
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Artrya Limited Business Overview & Revenue Model
Artrya Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -4.01M | -13.25M | -552.00K | -202.00K | -38.51K | -11.54K | EBIT |
| -7.52M | -14.40M | -12.42M | -16.61M | -4.24M | -1.76M | EBITDA |
| -18.75M | -13.96M | -10.51M | -16.40M | -4.01M | -1.34M | Net Income Common Stockholders |
| -14.56M | -14.00M | -11.14M | -17.16M | -4.08M | -1.35M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.76M | 7.28M | 20.41M | 35.56M | 50.13M | 2.23M | Total Assets |
| 16.66M | 19.01M | 33.09M | 43.87M | 52.22M | 2.66M | Total Debt |
| 789.00K | 949.00K | 1.21M | 1.37M | 47.00K | 10.62K | Net Debt |
| -6.83M | -6.18M | -19.07M | -13.92M | -50.08M | -2.22M | Total Liabilities |
| 1.97M | 2.21M | 2.53M | 3.23M | 1.17M | 162.39K | Stockholders Equity |
| 14.69M | 16.80M | 30.56M | 40.64M | 51.05M | 2.49M |
| Cash Flow | Free Cash Flow | ||||
| -4.11M | -15.41M | -16.69M | -15.99M | -3.55M | -1.64M | Operating Cash Flow |
| -12.01M | -15.41M | -10.74M | -9.61M | -1.49M | -1.62M | Investing Cash Flow |
| -41.72K | 2.71M | 15.83M | -26.59M | -1.86M | -15.48K | Financing Cash Flow |
| 4.54M | -299.00K | -245.00K | 38.53M | 14.10M | 2.96M |
Artrya Limited Technical Analysis
Artrya Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$206.74M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
44 Neutral | AU$120.03M | ― | -35.20% | ― | 4.68% | -155.42% | |
41 Neutral | $119.47M | ― | -99.05% | ― | ― | -34.09% | |
37 Underperform | ― | -75.75% | ― | ― | -23.52% | ||
36 Underperform | AU$3.32M | ― | -119.28% | ― | ― | 64.10% | |
36 Underperform | $21.48M | ― | -467.81% | ― | -75.71% | -8.26% |
Artrya Limited Corporate Events
Artrya Limited announced the issuance of 100,000 fully paid ordinary shares following the exercise of vested employee incentive restricted stock units. This move aligns with the company’s compliance with relevant provisions of the Corporations Act, indicating a strategic step in its operational and market positioning. The issuance reflects Artrya’s commitment to leveraging its workforce’s potential and could have implications for its growth and stakeholder engagement.
Artrya Limited has announced the quotation of 100,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code AYA, effective May 5, 2025. This move is part of the company’s ongoing efforts to expand its market presence and enhance liquidity, potentially benefiting shareholders and improving the company’s financial flexibility.
Artrya Limited has achieved a significant milestone by receiving FDA 510(k) clearance for its Salix® Coronary Anatomy, allowing for its commercial sale in the US. This clearance paves the way for its formal launch across US hospital systems. The company has also secured three-year contracts with Sonic Healthcare Australia and Lumus Imaging for the use of its platform. Additionally, Artrya is advancing its clinical validation efforts for other products, including the Salix® Coronary Plaque and Salix® Coronary Flow, in preparation for further FDA submissions. The successful capital raise of $15 million boosts its financial position, supporting ongoing operations and product development.
Artrya Limited announced the cessation of 592,500 securities due to the lapse of conditional rights, as the conditions for these securities were not met by the specified date. This development may impact the company’s capital structure and could influence investor perceptions, as it reflects on the company’s ability to meet certain operational or financial conditions.
Artrya Limited has achieved significant milestones in Q3 FY25, including receiving FDA 510(k) clearance for its Salix® Coronary Anatomy platform, enabling its commercial launch in the US. This clearance allows Artrya to expand its market presence by integrating its technology into major US hospital systems, providing a substantial growth opportunity. Additionally, Artrya secured three-year contracts with Sonic Healthcare and Lumus Imaging in Australia, further validating the clinical value of its platform. The company also completed a $15 million capital raise to support its operations and future developments.
Artrya Limited has announced the issuance of 2,054,795 unlisted options with an exercise price of $1.095, set to expire on April 8, 2027. This move is part of a previously announced transaction and reflects the company’s strategic efforts to strengthen its financial position and incentivize stakeholders, potentially impacting its market presence and operational capabilities.
Artrya Limited has announced the quotation of 13,749,448 ordinary fully paid securities on the Australian Securities Exchange as of April 8, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.
Artrya Limited has successfully completed Tranche 2 of its share placement, issuing over 13.7 million ordinary shares and more than 2 million unlisted options. This move, managed by Petra Capital, aims to bolster the company’s financial position as it continues to commercialize its AI platform for coronary artery disease detection. The completion of this placement is expected to enhance Artrya’s operational capabilities and strengthen its market position in the medical technology sector.
Artrya Limited announced that all resolutions at its General Meeting of Shareholders were passed. This approval, including the ratification of placement shares and broker options, supports the company’s strategic initiatives and strengthens its financial position, potentially enhancing its market presence and stakeholder confidence.
Artrya Limited has announced the application for quotation of 100,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code AYA. This move signifies a strategic step in enhancing the company’s market presence and potentially increasing its capital base, which could support further development and deployment of its healthcare technology solutions.
Artrya Limited announced the issuance of 100,000 ordinary shares following the exercise and conversion of vested employee incentive performance rights. This move reflects the company’s commitment to rewarding its employees and may have implications for its market positioning by potentially increasing shareholder value and enhancing employee motivation.
Artrya Limited has secured a significant commercial contract with Lumus Imaging for the use of its Salix® Coronary Anatomy platform, marking a major step in its commercial growth in Australia. This 36-month agreement will see the integration of Artrya’s AI-driven technology at Lumus Imaging’s St George centre in New South Wales, utilizing the advanced Photon Counting CT scanner to enhance cardiovascular disease diagnosis. The collaboration is expected to generate revenue through a SaaS subscription model and reinforces Lumus Imaging’s commitment to cutting-edge innovation in patient care.
Artrya Limited has received US FDA 510(k) clearance for its Salix® Coronary Anatomy, a non-invasive tool that provides a rapid assessment of coronary artery disease. This clearance allows Artrya to commercialize in the US market, where it has already established strategic agreements with several hospital groups. The launch of Salix® Coronary Anatomy marks a significant advancement in coronary artery disease diagnostics, promising to improve patient outcomes and reduce healthcare costs. The company plans to leverage insights gained from this process to expedite future product clearances, expanding its market presence and offering new diagnostic capabilities.
Artrya Limited has announced the issuance of 25,000 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial position and support its ongoing operations in the healthcare sector, potentially impacting its market presence and offering new opportunities for stakeholders.
Artrya Limited has announced the issuance of 25,000 ordinary shares following the exercise and conversion of vested employee incentive performance rights. This move reflects the company’s ongoing commitment to incentivize its workforce as it continues to advance its AI technology for coronary artery disease detection, potentially impacting its market positioning and stakeholder interests.
Artrya Limited has announced the issuance of 200,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code AYA. This move reflects the company’s strategic efforts to strengthen its financial position and potentially expand its market presence, which could have significant implications for its stakeholders and industry standing.
Artrya Limited announced the issuance of 200,000 ordinary shares following the exercise and conversion of vested employee incentive performance rights. This move is part of the company’s efforts to incentivize employees and align their interests with the company’s growth objectives. The issuance of shares reflects Artrya’s ongoing commitment to leveraging its patented AI platform to enhance coronary artery disease diagnostics, potentially impacting its market positioning and stakeholder interests positively.
Artrya Limited has submitted its response to the US FDA’s queries regarding its 510(k) application for the Salix® Coronary Anatomy product, which is part of the regulatory process for obtaining approval. The company expects to receive regulatory clearance by the end of March 2025, marking a significant milestone in its regulatory pathway. This development is crucial for Artrya’s operations and industry positioning, as it progresses towards offering its AI-based coronary disease detection technology in the US market.
Artrya Limited has announced a new issuance of 110,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code AYA. This move is part of the company’s strategic financial operations, potentially impacting its market presence and offering new opportunities for investors.
Artrya Limited announced the issuance of 110,000 ordinary shares following the conversion of vested employee incentive performance rights. This move reflects the company’s ongoing commitment to incentivizing its workforce and may enhance its operational capabilities in the medical technology sector, particularly in the development of AI-driven healthcare solutions.
Artrya Limited reported a loss of $7.44 million for the half-year ending December 31, 2024, marking an 8.2% increase in losses compared to the previous year. The company did not declare any dividends during this period, and its net tangible assets per ordinary security decreased from 14.07 cents to 11.08 cents, reflecting ongoing financial challenges.
Artrya Limited announced the issuance of 6,798,498 fully paid ordinary shares as part of a share placement. This issuance was conducted without disclosure under the Corporations Act, and the company confirmed compliance with relevant regulatory provisions. The move is part of its ongoing efforts to enhance its market operations and strengthen its position in the medical technology industry.
Artrya Limited has announced the quotation of 6,798,498 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the security code ‘AYA’. This move, part of previously announced transactions, is expected to bolster Artrya’s market presence and potentially enhance shareholder value by expanding its financial base and operational capabilities.
Artrya Limited announced the issuance of 262,856 fully paid ordinary shares following the exercise of vested employee incentive restricted stock units. This move is in line with the company’s compliance with relevant sections of the Corporations Act, indicating a strategic step in rewarding employees while maintaining regulatory standards.
Artrya Limited has announced the quotation of 262,856 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code AYA, effective from February 17, 2025. This development is part of the company’s strategy to enhance its financial standing and potentially increase liquidity for its stakeholders.
Artrya Limited has released new presentation materials pertaining to capital raising efforts, which are not intended for distribution in the United States. This release outlines important disclaimers, emphasizing that the materials do not constitute a formal offer or investment advice, and highlights potential implications for investors and stakeholders, including the inherent uncertainties in forward-looking statements.
Artrya Limited announced a proposed issue of securities, which includes the issuance of 2,054,795 unlisted options with an exercise price of $1.095 and an expiry of two years from the issue date. Additionally, 20,547,946 ordinary fully paid securities are to be issued. This move is part of the company’s efforts to raise capital, potentially impacting its financial position and market strategy. The issuance of these securities is expected to support Artrya’s ongoing projects and operational goals, and it may influence stakeholder interests as the company advances its market presence.
Artrya Limited announced a successful A$15 million capital raising through a two-tranche placement to professional investors, priced at A$0.73 per share. The proceeds will be utilized to fast-track regulatory applications for its Salix® products, enhance customer implementations, conduct clinical studies, and support the SAPPHIRE study aimed at expanding the software’s adoption in US hospitals. This strategic move underscores Artrya’s commitment to accelerating its commercial expansion and securing broader clinical credibility, positioning the company for further growth and stakeholder engagement.
Artrya Limited has entered into a three-year commercial contract with Sonic Healthcare Australia – Radiology for the utilization of its Salix® Coronary Anatomy platform. This agreement is expected to generate revenue from a Software-as-a-Service subscription model starting in the fourth quarter of the fiscal year 2025. The Salix platform, which aids in the detection of coronary artery disease, will be integrated across Sonic’s radiology centers that perform CCTA scans. This partnership marks a significant milestone for Artrya, enhancing its industry position by aligning with Australia’s second-largest diagnostic imaging provider and expanding the use of its AI-driven technology to improve heart disease diagnosis.
Artrya Limited has announced the cessation of 90,740 performance rights as the conditions for these securities have not been met or have become incapable of being satisfied. This development may affect the company’s issued capital and reflects the challenges in meeting the conditional requirements for these securities.